Assessing diaphragm function in patients with respiratory diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to measure respiratory muscle function and strength in patients suffering from respiratory diseases such as asthma, COPD, fibrosis, and pulmonary hypertension. The researchers will recruit 800 patients and evaluate diaphragm and accessory muscle function, lung function, exercise tolerance, and symptom burden in a lab setting. Participants will be followed up via phone at 3, 6, 12, and 18 months to assess the relationship between diaphragm function and dyspnea, as well as the prognostic significance of diaphragm dysfunction in predicting hospitalizations and steroid use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension
* is 18 years or older
* is mentally and physically able to understand the study and to follow instructions
* are legally competent
* signed declaration of consent

Exclusion Criteria:

* BMI \> 35
* current or treatments or diseases in the past which could influence the evaluation of the study
* Expected lack of willingness to actively participate in study-related measures
* alcohol or drug abuse
* disc herniation/prolapse
* epilepsy
* wheelchair bound
* in custody due to an official or court order
* in a dependent relationship or employment relationship with investigating physician or one of their deputy
* emergency inpatient hospital stay within 4 weeks before study-specific examinations

Where it's running

• RWTH Aachen University Hospital
  Aachen, North Rhine-Westphalia, Germany Recruiting

Study contacts

• Principal investigator: Jens Spiesshoefer, MD — Uniklinik RWTH Aachen
• Study coordinator: Jens Spiesshoefer, MD
• Email: jspiesshoefer@ukaachen.de
• Phone: 0049 2418037036

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pulmonary and cardiovascular rehabilitation program for chronic respiratory and heart conditions

  This study tests a rehabilitation program that combines exercise for people with chronic lung and heart conditions to see if it helps them feel better and improve their daily activities.

  Recruiting University of Campinas, Brazil · Campinas, São Paulo · NCT06772922

• Using hyperpolarized 129Xe MRI to assess lung function in healthy individuals and those with lung diseases

  This study is testing a special type of MRI using hyperpolarized gas to see how well it can check lung function in both healthy people and those with lung diseases like asthma and COPD.

  Recruiting Phase 1 University of Kansas Medical Center · Kansas City, Kansas · NCT04624490

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Right‑side heart response to exercise in people with COPD

  This project will test how the right side of the heart responds to moderate and high‑intensity exercise in adults 40 and older with COPD and whether a targeted moderate‑intensity cycling program can improve that response.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT07576894

• Asthma and COPD among workers at Navanakorn Industrial Zone in Thailand

  This project will test how common asthma and COPD are among adult workers at the Navanakorn Industrial Zone by asking about breathing symptoms and doing lung function (spirometry) tests.

  Recruiting Thammasat University · Pathum Thani, Changwat Pathum Thani · NCT07383896

• Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD

  This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 13 sites Phase 2 Pulmovant, Inc. · Santa Barbara, California and 12 other locations · NCT07333183

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.